Dana L Casey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/886048/publications.pdf

Version: 2024-02-01

		516561	580701
32	690	16	25 g-index
papers	citations	h-index	g-index
22	22	22	002
33	33	33	983
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Predicting Outcome in Patients with Rhabdomyosarcoma: Role of [18F]Fluorodeoxyglucose Positron Emission Tomography. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1136-1142.	0.4	61
2	Increased local failure for patients with intermediateâ€risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. Cancer, 2019, 125, 3242-3248.	2.0	55
3	Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies. Cancer Immunology Research, 2020, 8, 161-166.	1.6	48
4	Late Toxicities of Intensityâ€Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma. Pediatric Blood and Cancer, 2016, 63, 1608-1614.	0.8	46
5	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	3.0	38
6	Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 393-400.	0.4	36
7	Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma. Clinical Cancer Research, 2020, 26, 1135-1140.	3.2	33
8	Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma. Pediatric Blood and Cancer, 2015, 62, 445-449.	0.8	30
9	Whole Lung Irradiation for Adults With Pulmonary Metastases From Ewing Sarcoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1069-1075.	0.4	27
10	TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma. British Journal of Cancer, 2021, 125, 576-581.	2.9	26
11	Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma. Frontiers in Oncology, 2019, 9, 537.	1.3	21
12	Favorable outcomes after whole abdominopelvic radiation therapy for pediatric and young adult sarcoma. Pediatric Blood and Cancer, 2014, 61, 1565-1569.	0.8	20
13	Femoral Fracture in Primary Soft-Tissue Sarcoma of the Thigh and Groin Treated with Intensity-Modulated Radiation Therapy: Observed versus Expected Risk. Annals of Surgical Oncology, 2019, 26, 1326-1331.	0.7	20
14	Patterns of Failure for Rhabdomyosarcoma of the Perineal and Perianal Region. International Journal of Radiation Oncology Biology Physics, 2014, 89, 82-87.	0.4	19
15	Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1204-1209.	0.4	19
16	Rhabdomyosarcoma of the Head and Neck: A Multimodal Approach. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 058-064.	0.4	19
17	Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2021, 127, 275-283.	2.0	19
18	Doseâ€escalation is needed for gross disease in highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2018, 65, e27009.	0.8	17

#	Article	IF	CITATIONS
19	Second cancer risk in childhood cancer survivors treated with intensityâ€modulated radiation therapy (IMRT). Pediatric Blood and Cancer, 2015, 62, 311-316.	0.8	16
20	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. Blood Advances, 2021, 5, 4185-4197.	2.5	15
21	Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1151-1157.	0.4	14
22	Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group. International Journal of Cancer, 2020, 147, 1419-1426.	2.3	14
23	Ewing sarcoma in adults treated with modern radiotherapy techniques. Radiotherapy and Oncology, 2014, 113, 248-253.	0.3	13
24	Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, 486-493.	0.4	13
25	Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2019, 104, 409-414.	0.4	13
26	Clinical Outcomes of Recurrent Intracranial Meningiomas Treated with Proton Beam Reirradiation. International Journal of Particle Therapy, 2019, 5, 11-22.	0.9	12
27	Local control of parameningeal rhabdomyosarcoma: An expert consensus guideline from the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatric Blood and Cancer, 2022, 69, e29751.	0.8	8
28	Second cancer risk in childhood cancer survivors treated with intensityâ€modulated radiation therapy: An updated analysis of more than 10Âyears of followâ€up. Pediatric Blood and Cancer, 2022, 69, e29600.	0.8	7
29	High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. Journal of Neuro-Oncology, 2019, 142, 523-528.	1.4	4
30	Femoral Fracture in Primary Soft Tissue Sarcoma Treated with Intensity-Modulated Radiation Therapy with and Without Dose Constraints. Annals of Surgical Oncology, 2021, 28, 2700-2704.	0.7	3
31	The Role of Intraoperative Radiation in Early-stage Breast Cancer. Clinical Breast Cancer, 2021, 21, 103-111.	1.1	3
32	Dosimetric and Clinical Factors Associated With Breast Reconstruction Complications in Patients Receiving Postmastectomy Radiation. Practical Radiation Oncology, 2021, , .	1.1	1